Novo Nordisk A/S
NONOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,558,094,268 | $1,955,495,010 | $2,111,869,582 | $2,755,596,147 |
| - Cash | $32,084,000 | $18,435,000 | $38,938,000 | $15,655,000 |
| + Debt | $101,214,000 | $99,268,000 | $118,723,000 | $102,787,000 |
| Enterprise Value | $1,627,224,268 | $2,036,328,010 | $2,191,654,582 | $2,842,728,147 |
| Revenue | $74,976,000 | $76,857,000 | $78,087,000 | $85,683,000 |
| % Growth | -2.4% | -1.6% | -8.9% | – |
| Gross Profit | $57,072,000 | $64,011,000 | $65,197,000 | $72,659,000 |
| % Margin | 76.1% | 83.3% | 83.5% | 84.8% |
| EBITDA | $33,761,000 | $43,596,000 | $46,046,000 | $40,142,000 |
| % Margin | 45% | 56.7% | 59% | 46.8% |
| Net Income | $20,006,000 | $26,503,000 | $29,034,000 | $28,230,000 |
| % Margin | 26.7% | 34.5% | 37.2% | 32.9% |
| EPS Diluted | 4.5 | 5.96 | 6.53 | 6.33 |
| % Growth | -24.5% | -8.7% | 3.2% | – |
| Operating Cash Flow | $46,107,000 | $40,785,000 | $24,591,000 | $12,301,000 |
| Capital Expenditures | -$13,628,000 | -$16,275,000 | -$14,586,000 | -$16,558,000 |
| Free Cash Flow | $32,479,000 | $24,510,000 | $10,005,000 | -$4,257,000 |